Linked Life Data

18336946

Source:http://linkedlifedata.com/resource/pubmed/id/18336946

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-4-21
pubmed:abstractText
To prepare a water-insoluble camptothecin (CPT) delivery carrier, hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by chemical conjugation of hydrophobic 5beta-cholanic acid moieties to the hydrophilic glycol chitosan backbone. Insoluble anticancer drug, CPT, was easily encapsulated into HGC nanoparticles by a dialysis method and the drug loading efficiency was above 80%. CPT-encapsulated HGC (CPT-HGC) nanoparticles formed nano-sized self-aggregates in aqueous media (280-330 nm in diameter) and showed sustained release of CPT for 1 week. Also, HGC nanoparticles effectively protected the active lactone ring of CPT from the hydrolysis under physiological condition, due to the encapsulation of CPT into the hydrophobic cores in the HGC nanoparticles. The CPT-HGC nanoparticles exhibited significant antitumor effects and high tumor targeting ability towards MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. Tumor growth was significantly inhibited after i.v. injection of CPT-HGC nanoparticles at doses of 10 mg/kg and 30 mg/kg, compared to free CPT at dose of 30 mg/kg. The significant antitumor efficacy of CPT-HGC nanoparticles was attributed to the ability of the nanoparticles to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) fluorescence imaging systems. Thus, the delivery of CPT to tumor tissues at a high concentration, with the assistance of HGC nanoparticles, exerted a potent therapeutic effect. These results reveal the promising potential of HGC nanoparticles-encapsulated CPT as a stable and effective drug delivery system in cancer therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1873-4995
pubmed:author
pubmed:issnType
Electronic
pubmed:day
8
pubmed:volume
127
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
208-18
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18336946-Animals, pubmed-meshheading:18336946-Antineoplastic Agents, Phytogenic, pubmed-meshheading:18336946-Camptothecin, pubmed-meshheading:18336946-Cell Line, Tumor, pubmed-meshheading:18336946-Cell Survival, pubmed-meshheading:18336946-Chitosan, pubmed-meshheading:18336946-Drug Carriers, pubmed-meshheading:18336946-Drug Stability, pubmed-meshheading:18336946-Humans, pubmed-meshheading:18336946-Hydrolysis, pubmed-meshheading:18336946-Hydrophobic and Hydrophilic Interactions, pubmed-meshheading:18336946-Lactones, pubmed-meshheading:18336946-Mice, pubmed-meshheading:18336946-Mice, Nude, pubmed-meshheading:18336946-Nanoparticles, pubmed-meshheading:18336946-Neoplasms, pubmed-meshheading:18336946-Tissue Distribution, pubmed-meshheading:18336946-Tumor Burden, pubmed-meshheading:18336946-Xenograft Model Antitumor Assays
pubmed:year
2008
pubmed:articleTitle
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
pubmed:affiliation
Biomedical Research Center, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Republic of Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't